ABCL vs ISRG
AbCellera Biologics Inc. vs Intuitive Surgical — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
63
Buy
VS
ISRG
Intuitive Surgical
60
Buy
| Metric | ABCL | ISRG |
|---|
| AI Score |
63
|
60
|
| Price |
$12.50
|
$371.73
|
| P/E Ratio |
-19.65×
|
42.21×
|
| ROE |
-15.1%
|
16.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
66.7%
|
| Debt / Equity |
0.15×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.2
|
40.0
|
| Beta |
1.191
|
1.46
|
| Expected Upside |
—
|
+18.5%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus ISRG.
ABCL leads by 3 points.
ABCL scores 63/100 (Buy) versus ISRG at 60/100 (Buy).
ABCL Committee View
80% agreement
5 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — quarter-over-quarter growth rate is accelerating, not just positive. Risk Analyst remains cautious — bollinger bandwidth of 120.7% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Bollinger bandwidth of 120.7% signals elevated volatility — Risk
ISRG Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 45.2 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical